To assess the prognostic effect of subretinal deposits in eyes with central serous chorioretinopathy (CSC).
The study included 21 eyes with foveal detachment and subretinal deposits at presentation that underwent photodynamic therapy (PDT). No symptoms or signs of CSC were found in the fellow eyes. Microperimetry, autofluorescence imaging, and optical coherence tomography were performed in both eyes before and after PDT. Subgroup analyses included comparison of eyes with an initial episode versus a recurrent episode of CSC.
Four months after PDT, foveal sensitivity had improved significantly in both initial episode eyes and recurrent episode eyes, but sensitivity remained at 3.1 dB (SD = 3.06, P = 0.008) and 2.7 dB (SD = 3.55, P = 0.028), respectively, lower than in the fellow eyes. Four months after PDT, foveal thickness was 245 μm (SD = 24.2) in the initial episode eyes versus 285 μm (SD = 22.6) in the fellow eyes (P < 0.001) and 246 μm (SD = 33.7) in the recurrent episode eyes versus 291 μm (SD = 24.8) in the fellow eyes (P = 0.001).
Eyes with foveal detachment and subretinal deposits that underwent PDT for CSC did not recover to the functional and structural level of the asymptomatic fellow eyes, irrespective of the number of episodes of CSC. The study indicates that subretinal deposits are associated with irreversible foveal damage in CSC.
The study examined patients with central serous chorioretinopathy and unilateral foveal detachment with hyperautofluorescent subretinal deposits and found that despite reattachment and improved microperimetric sensitivity after photodynamic therapy, foveal thickness and retinal sensitivity remained subnormal compared with fellow eyes, irrespective of the number of episodes of serous detachment.
*Department of Ophthalmology, Glostrup Hospital, Glostrup, Denmark
†University of Copenhagen, Copenhagen, Denmark.
Reprint request: Anders Pryds, MD, Department of Ophthalmology, Glostrup Hospital, Nordre Ringvej 7, 2600 Glostrup, Denmark; e-mail: firstname.lastname@example.org
Supported by the Danish Eye Research Foundation, Danish Eye Health Society, and the Macula Vision Research Foundation.
The authors declare no conflict of interest.
On behalf of the Glostrup Hospital, M. Larsen has performed contract research and consultancy services for Novartis.